Composition having tissue-repairing activity, and use therefor
First Claim
Patent Images
1. A method for treating hepatitis comprising administering, to a subject in need thereof, a composition comprising:
- a component comprising an extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), the component not having a cytoplasmic domain of Siglec-9; and
a component comprising a monocyte chemotactic protein-1 (MCP-1) activity.
2 Assignments
0 Petitions
Accused Products
Abstract
A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.
7 Citations
15 Claims
-
1. A method for treating hepatitis comprising administering, to a subject in need thereof, a composition comprising:
-
a component comprising an extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), the component not having a cytoplasmic domain of Siglec-9; and a component comprising a monocyte chemotactic protein-1 (MCP-1) activity. - View Dependent Claims (2, 3, 4, 5)
-
-
6. A method for treating severe hepatitis comprising administering, to a subject in need thereof, a composition comprising:
-
a component comprising an extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), the component not having a cytoplasmic domain of Siglec-9; and a component comprising a monocyte chemotactic protein-1 (MCP-1) activity. - View Dependent Claims (7, 8, 9, 10)
-
-
11. A method of treating a spinal cord injury comprising administering, to a subject in need thereof, a composition comprising:
-
a component comprising an extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), the component not having a cytoplasmic domain of Siglec-9; a component comprising a monocyte chemotactic protein-1 (MCP-1) activity; and chondroitin sulfate proteoglycan. - View Dependent Claims (12, 13, 14, 15)
-
Specification